ethyl 5-acetyl-1-methyl-1H-pyrazole-3-carboxylate | 1227409-98-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 5-acetyl-1-methyl-1H-pyrazole-3-carboxylate
• 英文别名: ethyl 5-acetyl-1-methylpyrazole-3-carboxylate
• CAS: 1227409-98-4
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: QQZAXRZJBSRJBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 5-acetyl-1-methyl-1H-pyrazole-3-carboxylate 在 lithium hydroxide monohydrate 、 溴 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 溶剂黄146 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.25h， 生成 5-(2-((3,5-dichlorophenyl)amino)thiazol-4-yl)-N,N-diethyl-1-methyl-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery

  摘要：

  Tuberculosis remains one of the deadliest infectious diseases in the world, and the increased number of multidrug-resistant and extremely drug-resistant strains is a significant reason for concern. This makes the discovery of novel antitubercular agents a cogent priority. We have previously addressed this need by reporting a series of substituted 2-aminothiazoles capable to inhibit the growth of actively replicating, nonreplicating persistent, and resistant Mycobacterium tuberculosis strains. Clues from the structureactivity relationships lining up the antitubercular activity were exploited for the rational design of improved analogues. Two compounds, namely N-phenyl-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 7a and N-(pyridin-2-yl)-5-(2-(p-tolylamino)thiazol-4-yl)isoxazole-3-carboxamide 8a, were found to show high inhibitory activity toward susceptible M. tuberculosis strains, with an MIC90 of 0.1250.25 mu g/mL (0.330.66 mu M) and 0.060.125 mu g/mL (0.160.32 mu M), respectively. Moreover, they maintained good activity also toward resistant strains, and they were selective over other bacterial species and eukaryotic cells, metabolically stable, and apparently not susceptible to the action of efflux pumps.

  DOI：

  10.1021/acs.jmedchem.7b00793
• 作为产物：
  描述：

  5-乙酰基1H-吡唑-3-羧酸乙酯 、 碘甲烷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 以11%的产率得到ethyl 5-acetyl-1-methyl-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY

  摘要：

  揭示的是由通式（I）表示的化合物或其药用可接受盐，其作为5-HT2B受体的选择性拮抗剂是有用的。该化合物和盐可用于治疗或预防与5-HT2B受体相关的各种疾病和症状。

  公开号：

  US20110275628A1

文献信息

• PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Casuscelli Francesco

  公开号：US20140051708A1

  公开（公告）日：2014-02-20

  The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

  本发明涉及嘧啶基嘧唑衍生物，其调节蛋白激酶活性，因此在治疗由蛋白激酶活性失调引起的疾病方面具有用处。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• [EN] PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS PYRAZOLYL-PYRIMIDINE EN TANT QU'INHIBITEURS DES KINASES
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2012139930A1

  公开（公告）日：2012-10-18

  The present invention relates to pyrazolyl-pyrimidine derivatives which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them.

  本发明涉及嘧啶基嘧啶衍生物，其调节蛋白激酶活性，因此在治疗由蛋白激酶活性失调引起的疾病方面具有用处。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用这些化合物或含有它们的药物组合物治疗疾病的方法。
• [EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022010828A1

  公开（公告）日：2022-01-13

  The present invention provides a compound of Formula (I), and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

  本发明提供了一种化合物（I）的化合物，以及包含一种或多种所述化合物的药物组合物，并且使用所述化合物用于治疗或预防一种或多种可能受益于抑制血浆激肽酶的疾病状态的方法，包括遗传性血管性水肿、葡萄膜炎、后葡萄膜炎、濕性年龄相关性黄斑水肿、糖尿病性黄斑水肿、糖尿病视网膜病变和视网膜静脉阻塞。这些化合物是血浆激肽酶的选择性抑制剂。
• NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY
  申请人：RaQualia Pharma Inc

  公开号：EP2386546A1

  公开（公告）日：2011-11-16

  Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT2B receptor.

  本发明公开了通式 (I) 所代表的化合物或其药学上可接受的盐，可用作 5-HT2B 受体的选择性拮抗剂。该化合物和盐可用于治疗或预防与 5-HT2B 受体相关的各种疾病和病症。
• US8252790B2
  申请人：——

  公开号：US8252790B2

  公开（公告）日：2012-08-28